資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34932
|
| 標題: | Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients |
| 作者: | Huang, Yu-Shan
Cheng, Chien-Yu
Sun, Hsin-Yun
Cheng, Shu-Hsing
Lu, Po-Liang
Lee, Chen-Hsiang
Lee, Yuan-Ti
Tsai, Hung-Chin
Yang, Chia-Jui
Liu, Chun-Eng
Liou, Bo-Huang
Lin, Shih-Ping
Huang, Sung-Hsi
Ho, Mao-Wang
Tang, Hung-Jen
Hung, Chien-Ching |
| 貢獻者: | Natl Taiwan Univ Hosp, Dept Internal Med
Natl Taiwan Univ, Coll Med
Taoyuan Gen Hosp, Dept Infect Dis, Minist Hlth & Welf
Natl Yang Ming Chiao Tung Univ, Sch Publ Hlth
Taipei Med Univ, Sch Publ Hlth
Kaohsiung Med Univ & Coll Med, Dept Internal Med
Kaohsiung Chang Gung Mem Hosp, Dept Internal Med
Chang Gung Univ, Coll Med
Chung Shan Med Univ Hosp, Dept Internal Med
Chung Shan Med Univ, Sch Med
Kaohsiung Vet Gen Hosp, Dept Internal Med
Natl Yang Ming Chiao Tung Univ, Sch Med
Far Eastern Mem Hosp, Dept Internal Med
Changhua Christian Hosp, Dept Internal Med
Hsinchu MacKay Mem Hosp, Dept Internal Med
Taichung Vet Gen Hosp, Dept Internal Med
Natl Taiwan Univ Hosp, Dept Internal Med, Hsinchu Branch
Natl Taiwan Univ, Dept Trop Med & Parasitol, Coll Med
China Med Univ Hosp, Dept Internal Med
Chi Mei Med Ctr, Dept Internal Med
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
Natl Taiwan Univ Hosp, Dept Internal Med |
| 關鍵字: | viral hepatitis
antiretroviral therapy
bone mineral density
hepatitis D virus
hyperlipidemia
proximal renal tubulopathy
tenofovir |
| 日期: | 2023 |
| 上傳時間: | 2024-12-25 11:05:51 (UTC+8) |
| 出版者: | AMER SOC MICROBIOLOGY |
| 摘要: | Data regarding the durability of tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) in maintaining hepatitis B virus (HBV) viral suppression among HIV/HBV-coinfected patients are limited. Between February and October 2018, 274 HIV/HBV-coinfected participants who had achieved HIV RNA of <50 copies/mL with tenofovir disoproxil fumarate (TDF)-containing ART and switched to elvitegravir/cobicistat/emtricitabine/TAF were prospectively enrolled. Serial plasma HIV and HBV viral loads, HBV and hepatitis D virus (HDV) serology, renal parameters, metabolic profiles, and bone mineral density (BMD) were assessed through 96 weeks. At baseline and weeks 48, 72, and 96, 5.8%, 5.1%, 5.8%, and 5.1% of the participants had plasma HBV DNA of >= 20 IU/mL, and 0%, 0.7%, 1.5%, and 2.2% had HIV RNA of >= 50 copies/mL, respectively. Hepatitis B surface antigen (HBsAg) loss occurred in 1.5% of 274 participants, and hepatitis B e-antigen (HBeAg) loss or seroconversion occurred in 14.3% of 35 HBeAg-positive participants. Compared with baseline, the median urine protein-to-creatinine ratio (79 versus 63 mg/g, P < 0.001) and beta 2-microglobulin-to-creatinine ratio (165 versus 83 mu g/g, P < 0.001) continued to decrease at week 96. BMD of the spine and hip slightly increased (mean change, +0.9% and +0.5%, respectively). The median triglycerides, total cholesterol, low-density lipoprotein (LDL)-cholesterol and high-density lipoprotein (HDL)-cholesterol increased from baseline to week 96 (116 versus 141, 166 versus 190, 99 versus 117, and 42 versus 47 mg/dL, respectively; all P < 0.001), and most of the increases occurred in the first 48 weeks of the switch. Our study showed that switching from TDF-containing ART to elvitegravir/cobicistat/emtricitabine/TAF maintained HBV and HIV viral suppression through 96 weeks among HIV/HBV-coinfected patients. Proteinuria continued to improve, while fasting lipids increased and BMD stabilized at 96 weeks after the switch.IMPORTANCE Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as a maintenance therapy showed durable and high rates of viral suppression for HIV/HBV-coinfected patients, with only 5.1% and 2.2% of patients having HBV DNA of >= 20 IU/mL and HIV RNA of >= 50 copies/mL, respectively, at 96 weeks. Our study fills the data gap on the long-term clinical effectiveness of tenofovir alafenamide-containing antiretroviral therapy in people living with HIV who have HBV coinfection. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as a maintenance therapy showed durable and high rates of viral suppression for HIV/HBV-coinfected patients, with only 5.1% and 2.2% of patients having HBV DNA of >= 20 IU/mL and HIV RNA of >= 50 copies/mL, respectively, at 96 weeks. Our study fills the data gap on the long-term clinical effectiveness of tenofovir alafenamide-containing antiretroviral therapy in people living with HIV who have HBV coinfection. |
| 關聯: | Microbiology Spectrum, v.11, n.3 |
| 顯示於類別: | [行政單位] 456
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 2 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
